The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2015 | The 5-year update on the COMFORT-II clinical trial of ruxolitinib
Jean-Jacques Kiladjian, MD, PhD from the Saint-Louis Hospital & Paris Diderot University, Paris, France provides an overview of the COMFORT-II clinical trial, a Phase III study comparing ruxolitinib with best available therapy in patients with intermediate to high-risk myelofibrosis. Ruxolitinib improved the spleen response and reduced the symptoms of myelofibrosis, leading to an increase in quality of life that could be maintained over several years. Patients who received best available therapy and then switched to ruxolitinib after the primary end point was achieved, they were still able to experience the benefits of the drug.
